JP2007501257A5 - - Google Patents

Download PDF

Info

Publication number
JP2007501257A5
JP2007501257A5 JP2006522766A JP2006522766A JP2007501257A5 JP 2007501257 A5 JP2007501257 A5 JP 2007501257A5 JP 2006522766 A JP2006522766 A JP 2006522766A JP 2006522766 A JP2006522766 A JP 2006522766A JP 2007501257 A5 JP2007501257 A5 JP 2007501257A5
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
compound
independently
heteroatoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006522766A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007501257A (ja
JP4889489B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/025539 external-priority patent/WO2005013982A1/en
Publication of JP2007501257A publication Critical patent/JP2007501257A/ja
Publication of JP2007501257A5 publication Critical patent/JP2007501257A5/ja
Application granted granted Critical
Publication of JP4889489B2 publication Critical patent/JP4889489B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006522766A 2003-08-06 2004-08-06 プロテインキナーゼのインヒビターとして有用なアミノトリアゾール化合物 Expired - Fee Related JP4889489B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49278703P 2003-08-06 2003-08-06
US60/492,787 2003-08-06
PCT/US2004/025539 WO2005013982A1 (en) 2003-08-06 2004-08-06 Aminotriazole compounds useful as inhibitors of protein kinases

Publications (3)

Publication Number Publication Date
JP2007501257A JP2007501257A (ja) 2007-01-25
JP2007501257A5 true JP2007501257A5 (cg-RX-API-DMAC10.html) 2007-09-13
JP4889489B2 JP4889489B2 (ja) 2012-03-07

Family

ID=34135157

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006522766A Expired - Fee Related JP4889489B2 (ja) 2003-08-06 2004-08-06 プロテインキナーゼのインヒビターとして有用なアミノトリアゾール化合物

Country Status (11)

Country Link
US (2) US7226920B2 (cg-RX-API-DMAC10.html)
EP (1) EP1663211B1 (cg-RX-API-DMAC10.html)
JP (1) JP4889489B2 (cg-RX-API-DMAC10.html)
AR (1) AR045731A1 (cg-RX-API-DMAC10.html)
AT (1) ATE455546T1 (cg-RX-API-DMAC10.html)
AU (1) AU2004263148B2 (cg-RX-API-DMAC10.html)
CA (1) CA2534921C (cg-RX-API-DMAC10.html)
DE (1) DE602004025258D1 (cg-RX-API-DMAC10.html)
PE (1) PE20050338A1 (cg-RX-API-DMAC10.html)
TW (1) TW200514776A (cg-RX-API-DMAC10.html)
WO (1) WO2005013982A1 (cg-RX-API-DMAC10.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
ATE455546T1 (de) * 2003-08-06 2010-02-15 Vertex Pharma Aminotriazol-verbindungen als proteinkinase- hemmer
JP2007522233A (ja) 2004-02-11 2007-08-09 アムジエン・インコーポレーテツド バニロイド受容体リガンド及び治療におけるそれらの使用
PT1791830E (pt) 2004-09-17 2011-04-04 Vertex Pharma Compostos de diaminotriazole úteis como inibidores de proteína-quinase
PL1811998T3 (pl) 2004-10-21 2011-05-31 Vertex Pharma Triazole użyteczne jako inhibitory kinaz białkowych
CN100334084C (zh) * 2005-04-26 2007-08-29 武汉大学 联三唑化合物及其制备方法和用途
EP1896134A2 (en) 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
WO2007013830A1 (en) 2005-07-26 2007-02-01 Portela & Ca. S.A. Nitrocatechol derivatives as comt inhibitors
US7345178B2 (en) * 2005-08-04 2008-03-18 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
CA2621503C (en) 2005-09-07 2014-05-20 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
CA2663856A1 (en) 2006-09-28 2008-04-10 Exelixis, Inc. Jak-2 modulators and methods of use
AU2007305016B2 (en) 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
PL2848610T3 (pl) * 2006-11-15 2018-01-31 Ym Biosciences Australia Pty Inhibitory aktywności kinazy
KR20090092317A (ko) * 2006-12-11 2009-08-31 아이알엠 엘엘씨 키나제 억제제로서의 화합물 및 조성물
ES2406930T3 (es) 2006-12-29 2013-06-10 Rigel Pharmaceuticals, Inc. Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL
RS53281B (sr) 2006-12-29 2014-08-29 Rigel Pharmaceuticals Inc. Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori
CA2710051C (en) 2006-12-29 2017-05-16 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
CN101622248B (zh) 2006-12-29 2013-04-17 里格尔制药公司 用作axl抑制剂的n3-杂芳基取代的三唑和n5-杂芳基取代的三唑
CA2710230C (en) 2006-12-29 2016-02-23 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
DK2481410T3 (en) 2007-01-31 2016-10-24 Bial - Portela & Ca S A Nitrocatecholderivater as COMT inhibitors administered in a specific dosage regimen
CA2704052C (en) 2007-10-26 2015-04-21 Rigel Pharmaceuticals, Inc. Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
BRPI0908731A2 (pt) 2008-03-17 2017-05-16 Bial - Portela & C A S A formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol
CA2730251C (en) 2008-07-09 2016-08-09 Rigel Pharmaceuticals, Inc. Bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2730231C (en) 2008-07-09 2016-10-18 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2010078258A1 (en) * 2008-12-29 2010-07-08 The Board Of Trustees Of The University Of Alabama Compounds comprising two or more biologically functional ions and method of treating parkinson's disease
BRPI1007046B1 (pt) 2009-01-16 2019-07-16 Rigel Pharmaceuticals, Inc. Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático.
CN102448444B (zh) 2009-04-01 2016-05-25 巴尔-波特拉及康邦亚股份有限公司 包括硝基儿茶酚衍生物的药物制剂及其制备方法
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
LT2496567T (lt) 2009-11-05 2017-11-27 Rhizen Pharmaceuticals S.A. Nauji benzopirano kinazės moduliatoriai
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
JP2012102090A (ja) * 2010-10-15 2012-05-31 Sumitomo Chemical Co Ltd ピリミジン化合物およびその有害生物防除用途
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
MX2013010898A (es) 2011-03-24 2013-12-06 Chemilia Ab Novedoso derivados de la pirimidina.
PT2705029T (pt) 2011-05-04 2019-02-01 Rhizen Pharmaceuticals S A Novos compostos como moduladores de proteína quinases
CN102827073A (zh) * 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN103030646B (zh) * 2011-09-29 2016-08-24 上海恒瑞医药有限公司 苯并二氧六环类衍生物、其制备方法及其在医药上的应用
US9126988B2 (en) 2011-12-13 2015-09-08 Bial—Portela & Ca, S.A. Intermediate for preparing a catechol-O-methyltransferase inhibitor
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
WO2013106614A1 (en) * 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US20150182490A1 (en) 2012-06-26 2015-07-02 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
PT2870157T (pt) 2012-07-04 2017-11-27 Rhizen Pharmaceuticals S A Inibidores seletivos de delta pi3k
WO2014110200A1 (en) 2013-01-10 2014-07-17 Zisman Lawrence S Non-selective kinase inhibitors
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
ES2959419T3 (es) 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
AU2017251537B2 (en) 2016-04-15 2020-10-08 Abbvie Inc. Bromodomain inhibitors
RU2763525C2 (ru) 2016-10-27 2021-12-30 Пульмокин, Инк. Комбинированная терапия для лечения легочной гипертензии
WO2018106646A1 (en) * 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
US10617680B2 (en) * 2017-04-18 2020-04-14 Celgene Quanticel Research, Inc. Therapeutic compounds
GB201801226D0 (en) * 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8429307D0 (en) * 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
US5801031A (en) * 1996-04-05 1998-09-01 Health Research, Incorporated Human and rat gamma glutamyl hydrolase genes
SK6652000A3 (en) * 1997-11-11 2002-05-09 Pfizer Prod Inc Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
ES2221426T3 (es) * 1998-08-20 2004-12-16 Smithkline Beecham Corporation Nuevos compuestos de triazol sustituidos.
AU764479B2 (en) * 1998-10-29 2003-08-21 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
US6596747B2 (en) * 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
US6124272A (en) * 1999-04-09 2000-09-26 Isis Pharmaceutical Inc. Antisense modulation of PDK-1 expression
FR2802530B1 (fr) * 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
AU2001290912A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
NZ526624A (en) * 2000-12-22 2005-07-29 Ortho Mcneil Pharm Inc Substituted triazole diamine derivatives as kinase inhibitors
DE10123586A1 (de) * 2001-05-08 2002-11-28 Schering Ag 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren
US6846928B2 (en) 2002-03-15 2005-01-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
ATE455546T1 (de) * 2003-08-06 2010-02-15 Vertex Pharma Aminotriazol-verbindungen als proteinkinase- hemmer

Similar Documents

Publication Publication Date Title
CN113717156B (zh) Egfr抑制剂、其制备方法及用途
DE60114215T2 (de) Kondensierte pyrrolocarbazole gegen entzündungen
TW202144338A (zh) 嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用
US20130131068A1 (en) Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
WO2005035516A1 (ja) 新規縮合複素環化合物およびその用途
EP2616461A2 (en) Potent and selective inhibitors of hepatitis c virus
HU223666B1 (hu) Taxoidok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
WO2020142413A1 (en) Compositions and methods for modulating hair growth
JP2007530595A5 (cg-RX-API-DMAC10.html)
JP2006523202A (ja) 生体還元により活性化されるプロドラッグ
TWI923600B (zh) 含硫異吲哚啉類衍生物、其製備方法及其在醫藥上的應用
Zhou et al. Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC
JP2019520367A (ja) 新規なヘテロサイクリック誘導体化合物およびその用途
KR20060017763A (ko) 치료에 사용하는 아제티딘카르복스아미드 유도체의 용도
CN113825757B (zh) 取代的稠合双环类衍生物、其制备方法及其在医药上的应用
HU229937B1 (hu) Kondenzált azepinek mint vazopresszin agonisták, a vegyületek vagy ezek gyógyászatilag elfogadható sóinak alkalmazása gyógyszer-készítmény komponenseként vagy ennek elõállítására és a hatóanyagot tartalmazó gyógyszerkészítmény
US8895602B1 (en) 6-pyrazolylamido-3-substituted azabicyclo[3.1.0]hexane compounds as calcium channel inhibitors
ES2279452T3 (es) 6-((sustituido)fenil)triazolopirimidinas como agentes antineoplasicos.
EP1847534B1 (en) Thiadiazoline derivatives for treating cancer
RU2007134970A (ru) Производные пирролидинацетилена и пиперидинацетилена для применения в качестве антагонистов mglur5
ES2740428T3 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de la elastasa de neutrófilos
US9221799B2 (en) Anti-cancer agents
CN118271307A (zh) Prmt5-mta抑制剂
CN106554314A (zh) 苯甲酰胺类衍生物
RU2006122935A (ru) Новые производные бензимидазола и имидазопиридина и их применение в качестве лекарственных средств